Wysa

by Wysa  · Based in United States →Everyday Mental Health
Family Medicine Internal Medicine Psychiatry

Freemium
Documentation ProvidedRegulatory Status Disclosed

Overview

Wysa is an AI-powered mental health platform designed to provide conversational support and therapeutic interventions. It utilizes evidence-based techniques, including Cognitive Behavioral Therapy (CBT) and Dialectical Behavior Therapy (DBT), delivered through an AI chatbot. For physicians and mental health professionals, Wysa offers a unique tool to extend care, provide immediate support to clients, and gain insights into their well-being outside of traditional therapy sessions.

The platform is built to be accessible and engaging, offering a safe space for users to express themselves and learn coping strategies. Wysa’s AI can guide users through exercises, meditations, and goal-setting activities, helping to manage stress, anxiety, depression, and other mental health challenges. This can serve as a valuable adjunct to in-person or telehealth therapy, providing continuous support and reinforcement of therapeutic principles.

For clinicians, Wysa can offer aggregated, anonymized insights into patient engagement and progress, which can help tailor treatment plans and identify areas where clients might need more support. While Wysa is not a diagnostic tool and does not replace human therapy, it acts as a supportive companion that can enhance patient outcomes by promoting self-management and emotional regulation skills. Its focus on evidence-based techniques ensures that the support provided aligns with professional therapeutic standards.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI conversational chatbot
  • Evidence-based therapeutic techniques (CBT, DBT)
  • Guided meditations and exercises
  • Mood tracking and journaling
  • Goal setting and progress monitoring
  • Anonymized insights for clinicians
  • Crisis support resources
  • Personalized coping strategies

Use Cases

  • Supplemental mental health support for patients
  • Patient self-management of stress and anxiety
  • Reinforcement of therapeutic techniques between sessions
  • Early intervention for mental well-being
  • Providing insights for clinical treatment planning
  • Employee mental wellness programs

What Physicians Need to Know

Evidence Base
Wysa's AI conversational platform is rooted in Cognitive Behavioral Therapy (CBT) and Dialectical Behavior Therapy (DBT) principles. Its content and techniques are developed by a team of psychologists and coaches, aligning with established therapeutic guidelines for mental health support.
Clinical Validation Studies
Wysa has undergone clinical trials demonstrating its effectiveness. For instance, a study published in JMIR Mental Health showed that Wysa significantly reduced anxiety and depression scores. Another randomized controlled trial indicated its efficacy in improving mental well-being.
Clinical Workflow Integration
Wysa is primarily a direct-to-consumer and employer-based mental health support tool. While it doesn't directly integrate into physician EHR systems for diagnosis/treatment decisions, it can serve as a complementary tool for patient self-management and support, potentially reducing the burden on clinical staff for routine mental health check-ins.
Physician Tip

Wysa can be a valuable resource for patients needing accessible, evidence-based mental health support between physician visits or as a first step for those hesitant to seek traditional therapy. Physicians can recommend Wysa for self-management of mild to moderate anxiety and depression, stress reduction, and sleep improvement. It's important to emphasize that Wysa is a supportive tool and not a substitute for professional medical diagnosis or treatment.

Wysa primarily integrates with employer wellness programs and health plans, offering its services as a benefit. It does not typically integrate directly with clinical EHRs or other physician-facing decision support systems. Its 'integration' into a clinical context would be through physician recommendation to patients as an external resource.

Details

Category Clinical Decision Support & Reference, Mental & Behavioral Health AI, Patient Engagement & Education
Pricing Freemium
  • Wysa offers a free AI chat with limited features
  • The premium self-care version costs $74.99 annually with a seven-day free trial, or $19.99 per month
  • Coaching sessions with a human mental health coach start at $19.99 per session, or a monthly subscription of $79.99
Free TrialUnknown
DeploymentMobile App, Web Browser
Mobile App1
API AvailableUnknown
Data ExportUnknown
LanguagesEnglish, Hindi, Spanish
TrainingUnknown
Target SizeLarge Enterprise, Medium Enterprise, Public Health Systems
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Wysa received FDA Breakthrough Device Designation in May 2022 for its AI-based digital mental health conversational agent for adults (18 years and older) with chronic musculoskeletal pain (lasting longer than three months), depression, and anxiety.

GDPRUnknown AI-estimated
Integrations
EHR Not specified
Specialties Family Medicine, Internal Medicine, Psychiatry

Social Proof

CustomersOver 6 million people in 95 countries.
Notable
AccentureColgate-PalmoliveAetnaSwiss ReNHS.

Support & Reliability

Training ProvidedUnknown

What the Web Says

Wysa is an AI-powered mental wellness app that uses a chatbot, often personified as a penguin, to help users manage stress, anxiety, and other mental health concerns through evidence-based techniques like CBT and mindfulness. It's designed as a mental wellness assistant rather than a replacement for human therapy, offering 24/7 support and a non-judgmental space for users to express themselves. While generally well-received, its effectiveness is often highlighted for mild to moderate issues, with some users noting limitations in conversational depth and occasional repetitiveness.

Overall: Positive

Strengths

  • Available 24/7, providing immediate support during crises.
  • Offers a non-judgmental and confidential space for users to share their thoughts.
  • Utilizes evidence-based techniques like CBT, mindfulness, and guided exercises.
  • User-friendly interface with a calming aesthetic.
  • More affordable than traditional therapy, with a solid free version available.
  • Helps users develop coping strategies and improve mood.

Limitations

  • Conversations can feel scripted and repetitive, lacking depth and nuance.
  • May not be suitable for complex emotional issues or severe mental health conditions.
  • Limited free features, with some advanced tools and human coaching requiring payment.
  • AI may not always understand context or provide personalized insights.
  • Lack of long-term memory in conversations can make interactions less personal over time.
  • Some users experienced technical glitches or slow-loading elements.

Based on reviews from: Reddit, Medium, Ai Insights, Healthline, Apple App Store, Google Play Store, Review Hawk AI, Capterra, G2, Trustpilot, Blog (Noah AI vs Wysa), PMC (PubMed Central)

Last updated: 2026-06-19

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Wysa

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Endpoints News
Exclusive: Once a mental health chatbot, Wysa acquires physical therapy startup Kins
Wysa, an AI mental health platform, has acquired physical therapy startup Kins in an all-stock deal, expanding its services beyond mental health to include in-home physical therapy. This acquisition follows Wysa's earlier purchase of April Health, aiming to manage adjacent needs to primary care like mental health and chronic pain.
2025-09
Wysa News
Wysa Launches AI-Powered Chatbot to Streamline Mental Health Patient Intake in the US
Wysa has launched Wysa Gateway in the US, an AI-powered chatbot designed to automate clinical screenings and streamline patient intake for therapy providers and health plans. This tool has been proven in the UK's NHS, where it helped over 300,000 patients access therapy and achieved a 95% diagnostic accuracy rate.
2025-06
RxCap
Wysa Partners with RxCap to Advance Medication Adherence
Wysa announced a strategic partnership with RxCap to integrate remote monitoring technology for medication adherence into Wysa's care platform. This collaboration aims to provide healthcare clients with real-time insights into medication intake, enabling better patient outcomes and more effective care management.
2025-06
Business Wire
Wysa and April Health Merge to Revolutionize Access to Behavioral Health Care Through Primary Care Providers
Wysa and April Health have merged to integrate AI-driven mental health support into primary care, aiming to enhance accessibility and reduce wait times for behavioral health care. The collaboration will provide patients with continuous, personalized care through a combination of behavioral health specialists, psychiatrists, and Wysa's AI-driven guidance.
2025-03
Forbes
How Wysa Is Using AI To Make Mental Health Services More Accessible To Everyone
Wysa leverages AI and an app to provide therapeutic services for mental health, particularly benefiting health systems with large clinical teams by tracking patient progress in real-time and alerting therapists to changes in emotional state. The platform emphasizes human oversight to ensure anonymity and privacy, with optimism for AI to further enhance mental health tools.
2024-11
BioWorld
FDA grants breakthrough device designation for Wysa digital therapy | BioWorld
Wysa Ltd.'s AI-based digital therapy received FDA breakthrough device designation for adults with chronic musculoskeletal pain, depression, and anxiety. The device delivers cognitive behavioral therapy (CBT) via a smartphone-based conversational agent to reduce symptoms and improve physical function.
2022-05
Wysa News
Wysa Receives FDA Breakthrough Device Designation for AI-led Mental Health Conversational Agent
Wysa announced that the U.S. FDA granted Breakthrough Device Designation for its AI-based digital mental health conversational agent for patients with chronic musculoskeletal pain, depression, and anxiety. This designation follows an independent peer-reviewed clinical trial published in JMIR, which found Wysa effective for managing these conditions.
2022-05
JMIR mHealth and uHealth
An Empathy-Driven, Conversational Artificial Intelligence Agent (Wysa) for Digital Mental Well-Being: Real-World Data Evaluation Mixed-Methods Study
This study evaluated the effectiveness of the Wysa app in delivering positive psychology and mental well-being techniques through a text-based conversational mode to users with self-reported symptoms of depression. The findings indicated an improvement in self-reported symptoms of depression among more engaged app users.
2018-11

Videos

Product demos, reviews, and walkthroughs for Wysa.

View all on YouTube

Frequently Asked Questions

Wysa is primarily a patient-facing AI-powered conversational agent for mental health support and does not directly integrate with EHRs for clinical decision support in the traditional sense. Its role is more about providing early intervention, self-management tools, and symptom tracking, which can then be discussed with a physician. Data from Wysa can be shared with clinicians, but this typically requires manual input or specific integrations that would need to be established on a case-by-case basis.
Wysa has been shown in several studies to be effective in reducing symptoms of depression and anxiety. For example, a randomized controlled trial published in JMIR Mental Health found that Wysa significantly reduced PHQ-9 and GAD-7 scores compared to a waitlist control group. Wysa's modules are often based on evidence-based techniques like Cognitive Behavioral Therapy (CBT) and Dialectical Behavior Therapy (DBT), and it is a CE-marked medical device in Europe and an FDA-cleared digital therapeutic in the US for certain indications.
Wysa is not a diagnostic tool and should not be used as a substitute for professional medical advice or treatment. Its insights are based on user input and AI algorithms, and while helpful for self-management, they lack the nuanced understanding of a human clinician. Physicians should be cautious and always exercise their own clinical judgment, especially in cases of severe mental illness, suicidality, or complex comorbidities, where Wysa's capabilities are limited.
Yes, several other AI-powered mental health tools and digital therapeutics exist, each with varying features and levels of clinical decision support. Examples include Woebot, which also uses CBT principles, and various prescription digital therapeutics (PDTs) like Pear Therapeutics' reSET and reSET-O (though Pear Therapeutics has since ceased operations) or Akili Interactive's EndeavorRx, which are specifically designed for certain conditions and require a prescription. The 'superiority' depends on the specific clinical need and the evidence base for each tool.
Wysa offers both free and premium versions. The free version provides access to basic conversational AI support and some tools, while the premium version (Wysa Premium) unlocks more advanced features, guided programs, and access to human coaches. Pricing for individual users typically involves a subscription model. For healthcare systems, Wysa offers enterprise solutions, and pricing would be negotiated based on the scale of deployment and specific features required, impacting patient access based on whether the healthcare provider covers the cost or if it's an out-of-pocket expense for the patient.
Wysa states that it is HIPAA compliant and adheres to GDPR regulations, ensuring patient data privacy and security. They employ encryption, secure servers, and anonymization techniques to protect sensitive mental health information. Wysa's privacy policy details their data handling practices, emphasizing that user data is not shared without consent and is used to improve the personalized experience while maintaining confidentiality.

Related Tools

OCTA
OCTA
Clinical Decision Support & Reference
OCTA Flow is an AI-powered platform that assists ophthalmologists in analyzing Optical Coherence Tomography Angiography (OCTA) scans to enhance diagnostic accuracy and efficiency.
Elsevier
Elsevier
Clinical Decision Support & Reference
ClinicalKey AI is a clinical decision support tool that uses artificial intelligence to provide physicians with rapid access to evidence-based medical information.
EvidenceMD
EvidenceMD
Clinical Decision Support & Reference
EvidenceMD is an AI-powered clinical decision support platform that provides physicians with rapid access to current and relevant medical evidence for informed decision-making.
FAITH project
AI Agent
Clinical Decision Support & Reference
The FAITH project focuses on Federated Artificial Intelligence for Trusted Healthcare, aiming to develop secure and privacy-preserving AI solutions for healthcare, including potential applications for physician directories.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
Prof. Valmed
Prof. Valmed - validated medical information GmbH
Clinical Decision Support & Reference
Prof. Valmed is Europe's first CE Class IIb certified AI-supported medical co-pilot, providing healthcare professionals with validated, evidence-based medical information through an innovative AI platform.

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Last Verified: 2026-06-19 | First Added: 2026-06-19

Investors who backed Wysa

Funded through the company that built this tool.

AI Tool Finder
AI-powered search. Results may not be comprehensive.